Last edition
News about "TQC3721"
Sino Biopharma and AstraZeneca Sign Licensing Deal for TQC3721
Sino Biopharmaceutical has signed an exclusive licensing agreement with AstraZeneca to develop, manufacture, and commercialise TQC3721, a novel PDE3/4 inhibitor for respiratory diseases.
TQC3721 | 09/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members